Exelixis Inc. (NASDAQ: EXEL) reported second-quarter earnings of 29 cents per share, down 6.4% year-over-year. The bottom line surpassed the average analysts’ expectation of 23 cents per share.
Revenues of $240.3 million were up 29% compared to the same period last year and higher than the street view of $227 million. CABOMETYX net product revenues totaled $193.7 million, 32% higher than last year.
EXEL shares gained 0.23% during after-market trading on Wednesday. The stock has gained 7.5% so far this year.
Research and development expenses for the quarter were $81.9 million, compared to $42.5 million for the comparable period in 2018, primarily due to increases in clinical trial costs.
CEO Michael Morrissey said, “We achieved notable revenue growth for the CABOMETYX franchise, supporting our strategy of reinvestment in long-term growth opportunities through our internal discovery and targeted in-licensing activities, including today’s announcement of our partnership agreement with Aurigene.”
READ: Vertex Pharmaceuticals Q2 profit jumps 29%, beats estimates
For full-year 2019, cost of goods sold is expected to be between 4% and 5% of net product revenues, the company said. Research and development expenses are now expected to be between $330 million and $350 million given the impact of the recent business development activities.
Guidance for the effective tax rate in 2019 is between 21% and 23%.
Most Popular
Infographic: How Alaska Air Group (ALK) performed in Q1 2024
Alaska Air Group (NYSE: ALK) reported its first quarter 2024 earnings results today. Total operating revenue increased 2% year-over-year to $2.23 billion. Net loss amounted to $132 million, or $1.05 per
KMI Earnings: Kinder Morgan Q1 2024 adjusted profit increases; revenue drops
Kinder Morgan, Inc. (NYSE: KMI) reported higher adjusted earnings for the first quarter of 2024 despite a decrease in revenues. The energy infrastructure company also issued guidance for the full
What to expect when Altria (MO) reports first quarter 2024 earnings results
Shares of Altria Group, Inc. (NYSE: MO) stayed green on Wednesday. The stock has dropped 8% over the past one month. The tobacco giant is scheduled to report its first